Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. Issue 2 (December 2015) - Haas, Naomi; Stein, Mark; Tutrone, Ronald; Perini, Rodolfo; Denker, Andrew; Mauro, David; Fong, Lawrence